Loading...
Header Logo
Keywords
Last Name
Institution

STEVEN I SHERMAN

TitleProfessor
InstitutionMD Anderson
DepartmentEndocrine Neoplasia & HD
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer. Clin Cancer Res. 2019 Aug 01; 25(15):4862. PMID: 31371312.
      View in: PubMed
    2. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. 2019 Aug; 145(8):1977-1986. PMID: 31309300.
      View in: PubMed
    3. Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 Jun 11. PMID: 31186313.
      View in: PubMed
    4. Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck. 2019 Jun; 41(6):1928-1934. PMID: 30758123.
      View in: PubMed
    5. Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid. 2019 Apr; 29(4):530-539. PMID: 30654714.
      View in: PubMed
    6. Bagheri-Yarmand R, Sinha KM, Li L, Lu Y, Cote GJ, Sherman SI, Gagel RF. Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res. 2019 03; 17(3):751-760. PMID: 30552230.
      View in: PubMed
    7. Weitzman SP, Sherman SI. Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am. 2019 03; 48(1):253-268. PMID: 30717907.
      View in: PubMed
    8. Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab. 2018 10 01; 103(10):3698-3705. PMID: 30032208.
      View in: PubMed
    9. Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 Jun 01; 124(11):2365-2372. PMID: 29656442.
      View in: PubMed
    10. Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 04 01; 103(4):1277-1281. PMID: 29373711.
      View in: PubMed
    11. Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402. PMID: 29427212.
      View in: PubMed
    12. Hegedüs L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbøl JD, Daniels GH. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 03; 41(3):620-622. PMID: 29279300.
      View in: PubMed
    13. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599. PMID: 28911154.
      View in: PubMed
    14. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421. PMID: 28275168.
      View in: PubMed
    15. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 04; 75:213-221. PMID: 28237867.
      View in: PubMed
    16. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 04; 27(4):481-483. PMID: 28114862.
      View in: PubMed
    17. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128. PMID: 28155175.
      View in: PubMed
    18. Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751. PMID: 27673361.
      View in: PubMed
    19. Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877. PMID: 27662441.
      View in: PubMed
    20. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467. PMID: 27575943.
      View in: PubMed
    21. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4103-4109. PMID: 27548104.
      View in: PubMed
    22. Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864. PMID: 27525386.
      View in: PubMed
    23. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82. PMID: 27460442.
      View in: PubMed
    24. Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology. 2016; 90(6):339-46. PMID: 27207748.
      View in: PubMed
    25. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26(1):1-133. PMID: 26462967.
      View in: PubMed
    26. Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI. Follicular cell-derived thyroid cancer. Nat Rev Dis Primers. 2015 12 10; 1:15077. PMID: 27188261.
      View in: PubMed
    27. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015 Dec; 106(12):1714-21. PMID: 26426092.
      View in: PubMed
    28. Sherman S, Amzal B, Calvo E, Wang X, Park J, Liu Z, Lin C, Casciano R. An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. Clin Ther. 2015 Oct 22. PMID: 26602976.
      View in: PubMed
    29. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53. PMID: 26311725.
      View in: PubMed
    30. McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105. PMID: 26203804.
      View in: PubMed
    31. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90. PMID: 26200040.
      View in: PubMed
    32. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9. PMID: 26171797.
      View in: PubMed
    33. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56. PMID: 25913680.
      View in: PubMed
    34. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12; 372(7):621-30. PMID: 25671254.
      View in: PubMed
    35. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81. PMID: 25353071.
      View in: PubMed
    36. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888.
      View in: PubMed
    37. Carhill AA, Litofsky DR, Sherman SI. Unique characteristics and outcomes of patients diagnosed with both primary thyroid and primary renal cell carcinoma. Endocr Pract. 2015 May; 21(5):461-7. PMID: 25536972.
      View in: PubMed
    38. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680. PMID: 25505208.
      View in: PubMed
    39. Perrin A, Sherman S, Pal S, Chua A, Gorritz M, Liu Z, Wang X, Culver K, Casciano R, Garrison LP. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ. 2015 Mar; 18(3):200-9. PMID: 25422989.
      View in: PubMed
    40. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014 Oct; 24(10):1508-14. PMID: 25102375.
      View in: PubMed
    41. Haddad R, Sherman SI, Shah JP, Wirth LJ. New frontiers and treatment paradigms for thyroid carcinoma. Clin Adv Hematol Oncol. 2014 Jul; 12(7 Suppl 14):3-21; quiz 22. PMID: 25768715.
      View in: PubMed
    42. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106. PMID: 24617864.
      View in: PubMed
    43. Czerwonka L, Freeman J, McIver B, Randolph GW, Shah JP, Shaha AR, Sherman SI, Tuttle RM, Witterick IJ. Summary of proceedings of the second World Congress on Thyroid Cancer. Head Neck. 2014 Jul; 36(7):917-20. PMID: 24677329.
      View in: PubMed
    44. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26; 384(9940):319-28. PMID: 24768112.
      View in: PubMed
    45. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82. PMID: 24733667.
      View in: PubMed
    46. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94. PMID: 24628550.
      View in: PubMed
    47. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014 Jan; 24(1):35-42. PMID: 23731273.
      View in: PubMed
    48. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46. PMID: 24002501.
      View in: PubMed
    49. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013 Oct; 23(10):1277-83. PMID: 23489023.
      View in: PubMed
    50. Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61. PMID: 23676418.
      View in: PubMed
    51. Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol. 2013 Jul; 49(7):707-10. PMID: 23582411.
      View in: PubMed
    52. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun; 34(3):439-55. PMID: 23575762.
      View in: PubMed
    53. Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforov YE. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope. 2013 Apr; 123(4):1059-64. PMID: 23404751.
      View in: PubMed
    54. Sherman SI. The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer. Endocr Pract. 2013 Jan-Feb; 19(1):157-61. PMID: 23435044.
      View in: PubMed
    55. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42. PMID: 23185034.
      View in: PubMed
    56. Sherman SI. Emerging treatments in thyroid cancer. Clin Adv Hematol Oncol. 2012 Sep; 10(9):594-6. PMID: 23073125.
      View in: PubMed
    57. Cabanillas ME, Sherman SI. Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer. 2012 Apr; 19(2):C19-22. PMID: 22241721.
      View in: PubMed
    58. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012 Jun; 97(6):E878-87. PMID: 22496497.
      View in: PubMed
    59. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid. 2012 Apr; 22(4):347-55. PMID: 22280230.
      View in: PubMed
    60. Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid. 2011 Dec; 21(12):1309-16. PMID: 22136266.
      View in: PubMed
    61. Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol. 2012 Jan; 166(1):5-11. PMID: 21890651.
      View in: PubMed
    62. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011 Aug 11; 11:349. PMID: 21834960.
      View in: PubMed
    63. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab. 2011 Jul; 96(7):2027-31. PMID: 21734003.
      View in: PubMed
    64. Chang GC, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia Pac J Clin Oncol. 2011 Jun; 7 Suppl 2:34-40. PMID: 21585706.
      View in: PubMed
    65. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6. PMID: 21606412.
      View in: PubMed
    66. Di Lorenzo G, Casciano R, Malangone E, Buonerba C, Sherman S, Willet J, Wang X, Liu Z, De Placido S. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother. 2011 Jul; 12(10):1491-7. PMID: 21599551.
      View in: PubMed
    67. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol. 2011 Apr; 24 Suppl 2:S44-52. PMID: 21455200.
      View in: PubMed
    68. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252.
      View in: PubMed
    69. Moreno MA, Agarwal G, de Luna R, Siegel ER, Sherman SI, Edeiken-Monroe BS, Clayman GL. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2011 Feb; 137(2):157-62. PMID: 21339402.
      View in: PubMed
    70. Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L, Safe S. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog. 2011 Sep; 50(9):655-67. PMID: 21268135.
      View in: PubMed
    71. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec; 20(12):1423-4. PMID: 21054207.
      View in: PubMed
    72. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74. PMID: 21081783.
      View in: PubMed
    73. Bass MB, Sherman SI, Schlumberger MJ, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, Patterson SD. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab. 2010 Nov; 95(11):5018-27. PMID: 20739388.
      View in: PubMed
    74. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck. 2010 Jul; 32(7):829-36. PMID: 19885924.
      View in: PubMed
    75. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer. 2010 Jun 15; 116(12):2974-83. PMID: 20564403.
      View in: PubMed
    76. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol. 2010 Sep 01; 80(5):592-601. PMID: 20471374.
      View in: PubMed
    77. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010 Aug; 22(6):464-8. PMID: 20452757.
      View in: PubMed
    78. Sturgis EM, Sherman SI. Should papillary thyroid carcinoma be observed?: a word of caution. Arch Otolaryngol Head Neck Surg. 2010 May; 136(5):444-6. PMID: 20479372.
      View in: PubMed
    79. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30. PMID: 20495082.
      View in: PubMed
    80. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95. PMID: 20392874.
      View in: PubMed
    81. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010 Feb; 33(2):428-33. PMID: 20103558.
      View in: PubMed
    82. Ginsberg LE, Clayman GI, Edeiken-Monroe BS, Rohren E, Sherman SI. Not so fast on the thyroidectomy--response to Eloy, et al. AJNR Am J Neuroradiol. 2010 Feb; 31(2):E30; author reply E31. PMID: 20075083.
      View in: PubMed
    83. Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid. 2009 Dec; 19(12):1393-400. PMID: 20001721.
      View in: PubMed
    84. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec; 23(6):713-22. PMID: 19942148.
      View in: PubMed
    85. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8. PMID: 19903778.
      View in: PubMed
    86. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov; 19(11):1167-214. PMID: 19860577.
      View in: PubMed
    87. Tulloch-Reid M, Skarulis MC, Sherman SI, Sarlis NJ, Santarpia L. Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy. Anticancer Res. 2009 Nov; 29(11):4665-71. PMID: 20032418.
      View in: PubMed
    88. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009 Nov; 94(11):4171-9. PMID: 19850694.
      View in: PubMed
    89. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009 Nov; 94(11):4423-32. PMID: 19820016.
      View in: PubMed
    90. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009 Oct; 19(10):1043-8. PMID: 19772419.
      View in: PubMed
    91. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract. 2009 Sep-Oct; 15(6):605-11. PMID: 19546052.
      View in: PubMed
    92. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck. 2009 Sep; 31(9):1152-63. PMID: 19360746.
      View in: PubMed
    93. Smith GL, Smith BD, Garden AS, Rosenthal DI, Sherman SI, Morrison WH, Schwartz DL, Weber RS, Buchholz TA. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck. 2009 Aug; 31(8):1031-8. PMID: 19360741.
      View in: PubMed
    94. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10; 27(23):3794-801. PMID: 19564535.
      View in: PubMed
    95. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009 May; 49(5):1563-70. PMID: 19399911.
      View in: PubMed
    96. Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid. 2009 Apr; 19(4):407-12. PMID: 19355831.
      View in: PubMed
    97. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009 May; 94(5):1493-9. PMID: 19258410.
      View in: PubMed
    98. Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck. 2009 Mar; 31(3):419-23. PMID: 18798312.
      View in: PubMed
    99. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol. 2009 Jun; 40(6):827-33. PMID: 19200582.
      View in: PubMed
    100. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr; 94(4):1310-6. PMID: 19158200.
      View in: PubMed
    101. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1083-91. PMID: 19095376.
      View in: PubMed
    102. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology. 2009; 76(1):59-68. PMID: 19052478.
      View in: PubMed
    103. Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ. Four patients with cutaneous metastases from medullary thyroid cancer. Thyroid. 2008 Aug; 18(8):901-5. PMID: 18651821.
      View in: PubMed
    104. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 03; 359(1):31-42. PMID: 18596272.
      View in: PubMed
    105. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, Clayman GL, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. Head Neck. 2008 Jul; 30(7):883-8. PMID: 18213725.
      View in: PubMed
    106. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):511-24, xi. PMID: 18502340.
      View in: PubMed
    107. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008 Jan; 93(1):278-84. PMID: 17989125.
      View in: PubMed
    108. Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S. Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med. 2007 Nov-Dec; 11(6):1408-15. PMID: 18205710.
      View in: PubMed
    109. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008 Jan; 39(1):15-20. PMID: 17949783.
      View in: PubMed
    110. Sherman SI. New approaches to therapy of thyroid malignancies. Clin Adv Hematol Oncol. 2007 Jul; 5(7):539-41. PMID: 17679927.
      View in: PubMed
    111. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM. Thyroid carcinoma. J Natl Compr Canc Netw. 2007 Jul; 5(6):568-621. PMID: 17623612.
      View in: PubMed
    112. Sherman SI. Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma? Nat Clin Pract Endocrinol Metab. 2007 Jul; 3(7):510-1. PMID: 17519916.
      View in: PubMed
    113. Sherman SI, Ladenson PW. Subacute thyroiditis causing thyroid storm. Thyroid. 2007 Mar; 17(3):283. PMID: 17381366.
      View in: PubMed
    114. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec; 16(12):1229-42. PMID: 17199433.
      View in: PubMed
    115. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q. 2006 Dec; 22(4):231-8; discussion 239-40. PMID: 17146329.
      View in: PubMed
    116. Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007 Jan; 92(1):124-30. PMID: 17062760.
      View in: PubMed
    117. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006 Jun; 91(6):2205-8. PMID: 16595600.
      View in: PubMed
    118. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006 Apr; 47(4):648-54. PMID: 16595499.
      View in: PubMed
    119. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006 Jun; 91(6):2201-4. PMID: 16522694.
      View in: PubMed
    120. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006 Feb; 16(2):109-42. PMID: 16420177.
      View in: PubMed
    121. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar; 91(3):878-84. PMID: 16394083.
      View in: PubMed
    122. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar; 91(3):926-32. PMID: 16384850.
      View in: PubMed
    123. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR, Hay ID, Hertzberg BS, Intenzo CM, Jeffrey RB, Langer JE, Larsen PR, Mandel SJ, Middleton WD, Reading CC, Sherman SI, Tessler FN. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005 Dec; 237(3):794-800. PMID: 16304103.
      View in: PubMed
    124. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005 Jun; 15(6):531-44. PMID: 16029119.
      View in: PubMed
    125. Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Robbins R, Shah JP, Sisson JC, Thompson NW. Thyroid carcinoma. J Natl Compr Canc Netw. 2005 May; 3(3):404-57. PMID: 16002006.
      View in: PubMed
    126. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8594-602. PMID: 15623643.
      View in: PubMed
    127. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery. 2004 Dec; 136(6):1183-91. PMID: 15657574.
      View in: PubMed
    128. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26. PMID: 15287039.
      View in: PubMed
    129. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB. Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004 Apr; 198(4):525-34; discussion 534-5. PMID: 15051000.
      View in: PubMed
    130. Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassillopoulou-Sellin R, Lee JE, Evans DB. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg. 2003 Dec; 186(6):702-9; discussion 709-10. PMID: 14672783.
      View in: PubMed
    131. Pederson LC, Shapiro SE, Fritsche HA, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE. Potential role for intraoperative gamma probe identification of normal parathyroid glands. Am J Surg. 2003 Dec; 186(6):711-7. PMID: 14672784.
      View in: PubMed
    132. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003 Dec; 134(6):890-9; discussion 899-901. PMID: 14668720.
      View in: PubMed
    133. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003 Dec; 134(6):946-54; discussion 954-5. PMID: 14668727.
      View in: PubMed
    134. Shepler TR, Sherman SI, Faustina MM, Busaidy NL, Ahmadi MA, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthalmic Plast Reconstr Surg. 2003 Nov; 19(6):479-81. PMID: 14625496.
      View in: PubMed
    135. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, Reiners C. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003 Oct; 30(10):1371-7. PMID: 12856155.
      View in: PubMed
    136. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Apr; 88(4):1433-41. PMID: 12679418.
      View in: PubMed
    137. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003 Apr; 138(4):409-16; discussion 416. PMID: 12686527.
      View in: PubMed
    138. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer. 2003 Mar 01; 97(5):1186-94. PMID: 12599224.
      View in: PubMed
    139. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma. 2003 Mar; 3(4):249-52. PMID: 12672276.
      View in: PubMed
    140. Sherman SI. Thyroid carcinoma. Lancet. 2003 Feb 08; 361(9356):501-11. PMID: 12583960.
      View in: PubMed
    141. Royal RE, Delpassand ES, Shapiro SE, Fritsche HA, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery. 2002 Dec; 132(6):968-74; discussion 974-5. PMID: 12490843.
      View in: PubMed
    142. Ghori FY, Gutterman-Litofsky DR, Jamal A, Yeung SC, Arem R, Sherman SI. Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. Thyroid. 2002 Nov; 12(11):1009-16. PMID: 12490079.
      View in: PubMed
    143. Sherman SI. Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2002 Sep; 87(9):4059-62. PMID: 12213844.
      View in: PubMed
    144. Kouvaraki MA, Lee JE, Shapiro SE, Gagel RF, Sherman SI, Sellin RV, Cote GJ, Evans DB. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002 Jun; 137(6):641-7. PMID: 12049533.
      View in: PubMed
    145. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery. 2001 Dec; 130(6):921-30. PMID: 11742318.
      View in: PubMed
    146. McCutcheon IE, Kitagawa RH, Sherman SI, Bruner JM. Adenocarcinoma of the salivary gland metastatic to the pituitary gland: case report. Neurosurgery. 2001 May; 48(5):1161-5; discussion 1165-6. PMID: 11334286.
      View in: PubMed
    147. Tyler DS, Shaha AR, Udelsman RA, Sherman SI, Thompson NW, Moley JF, Evans DB. Thyroid cancer: 1999 update. Ann Surg Oncol. 2000 Jun; 7(5):376-98. PMID: 10864346.
      View in: PubMed
    148. Sherman S, Udelsman R, Duh QY. How should you choose a thyroid surgeon? Thyroid. 2000 May; 10(5):439-41. PMID: 10884193.
      View in: PubMed
    149. Sherman SI. The management of metastatic differentiated thyroid carcinoma. Rev Endocr Metab Disord. 2000 Apr; 1(3):165-71. PMID: 11705002.
      View in: PubMed
    150. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999 Nov; 84(11):3877-85. PMID: 10566623.
      View in: PubMed
    151. Fleming JB, Lee JE, Bouvet M, Schultz PN, Sherman SI, Sellin RV, Friend KE, Burgess MA, Cote GJ, Gagel RF, Evans DB. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 1999 Nov; 230(5):697-707. PMID: 10561095.
      View in: PubMed
    152. Sturgis CD, Caraway NP, Johnston DA, Sherman SI, Kidd L, Katz RL. Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer. 1999 Jun 25; 87(3):155-60. PMID: 10385447.
      View in: PubMed
    153. Arem R, Padayatty SJ, Saliby AH, Sherman SI. Thyroid microcarcinoma: prevalence, prognosis, and management. Endocr Pract. 1999 May-Jun; 5(3):148-56. PMID: 15251688.
      View in: PubMed
    154. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999 Apr 08; 340(14):1075-9. PMID: 10194237.
      View in: PubMed
    155. Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol. 1999 Jan-Feb; 16(1):12-5. PMID: 9890734.
      View in: PubMed
    156. Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol. 1999 Jan-Feb; 16(1):30-3. PMID: 9890737.
      View in: PubMed
    157. Lee JE, Evans DB, Hickey RC, Sherman SI, Gagel RF, Abbruzzese MC, Abbruzzese JL. Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery. 1998 Dec; 124(6):1115-22. PMID: 9854592.
      View in: PubMed
    158. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 1998 Dec; 83(12):4195-203. PMID: 9851751.
      View in: PubMed
    159. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998 Oct 15; 129(8):622-7. PMID: 9786809.
      View in: PubMed
    160. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998 Sep; 8(9):737-44. PMID: 9777742.
      View in: PubMed
    161. Sherman SI. Staging of thyroid carcinoma--reply. Cancer. 1998 Sep 01; 83(5):848-50. PMID: 9731885.
      View in: PubMed
    162. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998 Sep 01; 83(5):1012-21. PMID: 9731906.
      View in: PubMed
    163. Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid. 1998 Aug; 8(8):667-71. PMID: 9737361.
      View in: PubMed
    164. Sherman SI. The risks of thyroidectomy: words of caution for referring physicians. J Gen Intern Med. 1998 Jan; 13(1):60-1. PMID: 9462498.
      View in: PubMed
    165. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997 Nov; 82(11):3637-42. PMID: 9360519.
      View in: PubMed
    166. Lee JE, Evans DB, Sherman SI, Gagel RF. Evaluation of the incidental adrenal mass. Am J Med. 1997 Sep; 103(3):249-50. PMID: 9316558.
      View in: PubMed
    167. Sherman SI, Ringel MD, Smith MJ, Kopelen HA, Zoghbi WA, Ladenson PW. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab. 1997 Jul; 82(7):2153-8. PMID: 9215287.
      View in: PubMed
    168. Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med. 1996 Aug; 101(2):192-8. PMID: 8757360.
      View in: PubMed
    169. Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med. 1994 Jun; 96(6):531-5. PMID: 8017451.
      View in: PubMed
    170. Sherman SI, Tielens ET, Sostre S, Wharam MD, Ladenson PW. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994 Mar; 78(3):629-34. PMID: 8126134.
      View in: PubMed
    171. Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer. 1994 Jan 15; 73(2):424-31. PMID: 8293410.
      View in: PubMed
    172. Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab. 1992 Sep; 75(3):901-5. PMID: 1517383.
      View in: PubMed
    173. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A. 1992 Jun 15; 89(12):5251-5. PMID: 1376915.
      View in: PubMed
    174. Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest. 1992 Mar; 15(3):185-90. PMID: 1624678.
      View in: PubMed
    175. Sherman SI, Ladenson PW. Percutaneous transluminal coronary angioplasty in hypothyroidism. Am J Med. 1991 Mar; 90(3):367-70. PMID: 2003519.
      View in: PubMed
    176. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine. The Lancet Oncology. 17:1272-1282.
    177. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4103-4109.
    178. Overview of radioactive iodine-resistant differentiated thyroid cancer. Clinical Advances in Hematology and Oncology. 12:3-5.
    179. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 26:1744-1751.
    180. Why thyroid cancer?. Thyroid. 15:303-304.
    181. Surgical management of hereditary pheochromocytoma. Journal of the American College of Surgeons. 198:534-535.
    182. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 122:3856-3864.
    183. Erratum. Proceedings of the National Academy of Sciences of the United States of America. 89:8856.
    184. Molecular mechanisms in thyroid cancer biology. Clinical Advances in Hematology and Oncology. 12:10-13.
    185. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 26:1-133.
    186. Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis. Thyroid. 25:1097-1105.
    187. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer (The Journal of Clinical Endocrinology and Metabolism (2010) 95, (5018-5027)). Journal of Clinical Endocrinology and Metabolism. 96:252.
    188. Thyroid cancer. 295-310.
    189. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clinical Cancer Research. 22:44-53.
    190. Cancer disparities and thyroid carcinoma. Current Opinion in Endocrinology and Diabetes. 13:451-454.
    191. The author replies. New England Journal of Medicine. 359:2727.
    192. Carcimona of the thyroid. Seminars in Surgical Oncology. 16:3-4.
    193. Thyroid Cancer.
    194. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Archives of Dermatological Research. 1-9.
    195. Thyroid lymphoma. 615-619.
    196. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life. Thyroid. 25:1085-1090.
    197. Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4461-4467.
    198. Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. Oncology (Switzerland). 90:339-346.
    199. Anaplastic carcinoma clinical aspects. 629-632.
    200. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    201. Endocrine Complications of Head and Neck Surgery. 85-103.
    202. Erratum to "Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma" [Hum Pathol 40 (2009) 827-833] (DOI. Human Pathology. 40:1212.
    203. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    204. Bone metastases and skeletal-related events in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 101:4871-4877.
    205. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Science. 106:1714-1721.
    206. Anaplastic carcinoma prognosis. 647-649.
    207. Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 100:E77-E81.
    SHERMAN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description